Differential expression of WNT5A long and short isoforms in non-muscle-invasive bladder urothelial carcinoma
Authors:
- 1 June 2024
- journal article
- research article
- Vol. 39 (6) , 715-727
Abstract
Wnt ligands belong to a family of secreted glycoproteins in which binding to a range of receptors/co-receptors activates several intracellular pathways. WNT5A, a member of the Wnt family, is classified as a non-canonical Wnt whose activation triggers planar cell polarity (PCP) and Ca +2 downstream pathways. Aberrant expression of WNT5A has been shown to play both protective and harmful roles in an array of conditions, such as inflammatory disease and cancer. In the present study, using histological, immunohistochemical, and molecular methods, we investigated the expression of two isoforms of WNT5A, WNT5A-Short (WNT5A-S) and WNT5A-Long (WNT5A-L) in bladder urothelial carcinoma (UC). Three UC cell lines (RT4, J82, and T24), as well as a normal urothelial cell line, and formalin -fixed, paraffin-embedded (FFPE) transurethral resection (TUR) tissue samples from 17 patients diagnosed with UC were included in the study. WNT5A-L was the predominantly expressed isoform in urothelial cells, although WNT5A-S was also detectable. Further, although no statistically significant difference was found between the percentage of WNT5A-S transcripts in low-grade versus high-grade tumors, we did find a difference between the percentage of WNT5A-S transcripts found in non -invasion versus invasion of the lamina propria, subgroups of non-muscle-invasive tumors. In conclusion, both WNT5A-S and WNT5A-L isoforms are expressed in UC, and the percentage of their expression levels suggests that a higher proportion of WNT5A-S transcription may be associated with lamina propria invasion, a process preceding muscle invasion.Keywords
This publication has 45 references indexed in Scilit:
- Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian ExpertsCurrent Oncology Reports, 2023
- Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Tumor‐derived exosomal BCYRN1 activates WNT5A/VEGF‐C/VEGFR3 feedforward loop to drive lymphatic metastasis of bladder cancerClinical and Translational Medicine, 2021
- The human WNT5A isoforms display similar patterns of expression but distinct and overlapping activities in normal human osteoblastsJournal of Cellular Biochemistry, 2021
- The involvement of noncanonical Wnt signaling in cancersBiomedicine & Pharmacotherapy, 2021
- Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 TumorsEuropean Urology, 2019
- miR-129-5p inhibits gemcitabine resistance and promotes cell apoptosis of bladder cancer cells by targeting Wnt5aInternational Urology and Nephrology, 2018
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder TumoursEuropean Urology, 2016
- WNT-5A: signaling and functions in health and diseaseCellular and Molecular Life Sciences, 2015
- Wnt5a: A player in the pathogenesis of atherosclerosis and other inflammatory disordersAtherosclerosis, 2014